Retail Investors Are Hangzhou Biotest Biotech Co.,Ltd.'s (SHSE:688767) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥404m Last Week
Retail Investors Are Hangzhou Biotest Biotech Co.,Ltd.'s (SHSE:688767) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥404m Last Week
Key Insights
關鍵見解
- The considerable ownership by retail investors in Hangzhou Biotest BiotechLtd indicates that they collectively have a greater say in management and business strategy
- 55% of the business is held by the top 3 shareholders
- Insider ownership in Hangzhou Biotest BiotechLtd is 28%
- 散戶投資者對杭州百拓生物技術有限公司的大量所有權表明,他們在管理和業務戰略方面集體擁有更大的發言權
- 55% 的業務由前三名股東持有
- 杭州百拓生物技術有限公司的內部所有權爲28%
To get a sense of who is truly in control of Hangzhou Biotest Biotech Co.,Ltd. (SHSE:688767), it is important to understand the ownership structure of the business. We can see that retail investors own the lion's share in the company with 35% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
了解誰真正控制了杭州百拓生物技術有限公司, Ltd.(上海證券交易所代碼:688767),了解企業的所有權結構很重要。我們可以看到,散戶投資者擁有該公司的大部分股份,所有權爲35%。也就是說,如果股票上漲,該集團將受益最大(如果出現低迷,則損失最大)。
Clearly, retail investors benefitted the most after the company's market cap rose by CN¥404m last week.
顯然,在上週該公司的市值上漲了4.04億元人民幣之後,散戶投資者受益最大。
Let's delve deeper into each type of owner of Hangzhou Biotest BiotechLtd, beginning with the chart below.
讓我們從下圖開始,深入研究杭州百拓生物技術有限公司的每種類型的所有者。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240501/0-3dae5bc3da487f94b705218d600ea09e-0-a2a775d655baa0062a20fdf9cee7cd0e.png/big)
What Does The Institutional Ownership Tell Us About Hangzhou Biotest BiotechLtd?
關於杭州百拓生物技術有限公司,機構所有權告訴我們什麼?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
許多機構根據近似於當地市場的指數來衡量自己的表現。因此,他們通常會更多地關注主要指數中包含的公司。
Less than 5% of Hangzhou Biotest BiotechLtd is held by institutional investors. This suggests that some funds have the company in their sights, but many have not yet bought shares in it. If the company is growing earnings, that may indicate that it is just beginning to catch the attention of these deep-pocketed investors. It is not uncommon to see a big share price rise if multiple institutional investors are trying to buy into a stock at the same time. So check out the historic earnings trajectory, below, but keep in mind it's the future that counts most.
杭州百拓生物技術有限公司不到5%的股份由機構投資者持有。這表明一些基金將目光投向了該公司,但許多基金尚未購買該公司的股票。如果該公司正在增加收益,那可能表明它才剛剛開始引起這些財力雄厚的投資者的注意。如果多個機構投資者試圖同時買入股票,股價大幅上漲的情況並不少見。因此,請查看下面的歷史收益軌跡,但請記住,最重要的是未來。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240501/0-3dae5bc3da487f94b705218d600ea09e-1-347a7406a937c5048aaa91914dc78cb6.png/big)
We note that hedge funds don't have a meaningful investment in Hangzhou Biotest BiotechLtd. Our data shows that Hangzhou Tuokang Investment Co., Ltd. is the largest shareholder with 23% of shares outstanding. For context, the second largest shareholder holds about 20% of the shares outstanding, followed by an ownership of 11% by the third-largest shareholder. Additionally, the company's CEO Shujiang Wu directly holds 2.1% of the total shares outstanding.
我們注意到,對沖基金沒有對杭州百拓生物技術有限公司進行有意義的投資。我們的數據顯示,杭州拓康投資有限公司是最大股東,已發行股份的23%。就背景而言,第二大股東持有約20%的已發行股份,其次是第三大股東持有11%的所有權。此外,該公司首席執行官吳樹江直接持有已發行股份總額的2.1%。
After doing some more digging, we found that the top 3 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
在進一步挖掘之後,我們發現前三名股東共同控制了公司一半以上的股份,這意味着他們擁有影響公司決策的巨大權力。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.
雖然研究公司的機構所有權數據是有意義的,但研究分析師的情緒以了解風向哪個方向吹來也是有意義的。據我們所知,沒有分析師對該公司進行報道,因此它可能處於雷達之下。
Insider Ownership Of Hangzhou Biotest BiotechLtd
杭州百拓生物技術有限公司的內部所有權
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
不同國家對內部人員的定義可能略有不同,但董事會成員總是計算在內。公司管理層經營業務,但首席執行官將向董事會負責,即使他或她是董事會成員。
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。
Our most recent data indicates that insiders own a reasonable proportion of Hangzhou Biotest Biotech Co.,Ltd.. It has a market capitalization of just CN¥3.1b, and insiders have CN¥862m worth of shares in their own names. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.
我們最新的數據表明,內部人士擁有杭州百拓生物技術有限公司合理比例的股份。,有限公司。它的市值僅爲31億元人民幣,內部人士以自己的名義持有價值8.62億元人民幣的股票。這可能表明創始人仍然擁有大量股份。你可以點擊這裏查看他們是否在買入或賣出。
General Public Ownership
一般公有制
With a 35% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Hangzhou Biotest BiotechLtd. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
杭州百拓生物技術有限公司擁有35%的所有權,主要由個人投資者組成,對杭州百拓生物技術有限公司有一定程度的影響力。這種所有權規模雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。
Private Company Ownership
私人公司所有權
We can see that Private Companies own 35%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
我們可以看到,私人公司擁有已發行股份的35%。僅憑這一事實很難得出任何結論,因此值得研究誰擁有這些私營公司。有時,內部人士或其他關聯方通過單獨的私人公司對上市公司的股份擁有權益。
Next Steps:
後續步驟:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For example, we've discovered 3 warning signs for Hangzhou Biotest BiotechLtd that you should be aware of before investing here.
我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,我們發現了杭州百拓生物技術有限公司的3個警告信號,在投資這裏之前,你應該注意這些信號。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。